Cellebrite stock trades 23.95 percent below USD 14.13 consensus target

Published on 10/15/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 16.00 percent to USD 131.14 million. Cellebrite stock costs EUR 10.17 on October 15, 2026 at 9:44 p.m. CEST.

Analyst target and November date

Nine analysts set a USD 14.13 consensus target on October 14, 2026.
Second-quarter revenue rose 16.00 percent to USD 131.14 million.
Cellebrite stock costs EUR 10.17 at Lang & Schwarz on October 15, 2026 at 9:44 p.m. CEST.
Cellebrite is estimated to report third-quarter results on November 11, 2026.

CLBT, IL0011794802, Illustration mit AI erstellt.

Cellebrite stock had a USD 14.13 consensus target from nine analysts on October 14, 2026, leaving the target 23.95 percent above the USD 11.40 Nasdaq price. kaplio.com listed nine Buy ratings and no Hold or Sell ratings. Cellebrite stock was trading at EUR 10.17 at Lang & Schwarz on October 15, 2026 at 9:44 p.m. CEST.

Second-quarter revenue reached USD 131.14 million

Cellebrite reported second-quarter 2026 revenue of USD 131.14 million, up 16.00 percent from the comparable quarter of 2025. The company also reported adjusted EBITDA of USD 31.80 million, equal to a 24.00 percent margin, while subscription revenue reached USD 119.50 million.

The company had 1,287 employees at the end of June 2026, and annual recurring revenue rose 21.00 percent to USD 508.00 million. The earnings call also said defense and intelligence annual recurring revenue grew 25.00 percent in the second quarter. These figures came from the Q2 2026 earnings call transcript published by Yahoo Finance.

Nasdaq price sits below yearly high

On Nasdaq, Cellebrite last traded at USD 11.40 on October 15, 2026 at 3:52 p.m. ET. The home-market price stood 19.00 percent above its USD 9.58 52-week low and 42.94 percent below its USD 19.98 52-week high. Trading volume was 2,088,021 shares against an average of 2,974,845 shares.

The company had a USD 2.9 billion market capitalization and a trailing P/E ratio of 48.70 as of October 15, 2026. The zero dividend yield leaves the analyst target and the next earnings date as the main valuation and calendar markers.

Valuation and November 11 date

MarketBeat estimated that Cellebrite would report third-quarter 2026 results on November 11, 2026, with consensus revenue of USD 145.89 million and consensus earnings per share of USD 0.17. The source described the date as an estimate and listed a 5:00 p.m. ET conference call. MarketBeat also reported prior-year third-quarter revenue of USD 126.03 million.

Comparison with peers

Cellebrite: P/E 48.70, market capitalization USD 2.9 billion.

Palantir Technologies (Nasdaq, USD): minus 0.56 percent, P/E 169.69, market capitalization USD 459.8 billion.

Motorola Solutions (NYSE, USD): plus 0.86 percent, P/E 35.97, market capitalization USD 75.4 billion.

German euro quote after hours

The Nasdaq price, the analyst consensus and the November reporting date place Cellebrite's German euro quotation in a broader market frame. The next scheduled earnings release is November 11, 2026, while the latest reported quarter supplies the most recent operating comparison.

The further course of trading is shown by the continuously updated real-time quote of Cellebrite stock.